Astex Pharmaceuticals Provides SGI-110 Update

Oral Presentation at AACR Supports Potential of SGI-110 In The Treatment Of Platinum-Resistant Ovarian Cancer Clinical Update on SGI-110-01 Study

DUBLIN, Calif., April 10, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that SGI-110 was featured in an oral presentation on Tuesday, April 9 at the American Association of Cancer Research (AACR) in Washington, DC.

Researchers from Indiana University presented data from preclinical models supporting the ovarian cancer epigenetic chemosensitization effect of SGI-110. In established ovarian cancer xenograft models, SGI-110 in combination with platinum significantly delayed tumor growth compared to platinum alone. The researchers also showed that SGI-110 induced demethylation and increased expression of several tumor suppressor and tumor differentiation genes. In addition, SGI-110 slowed the repair of platinum DNA damage.

These data support the ongoing clinical randomized phase 2 study in which SGI-110 in combination with carboplatin is being studied in platinum-resistant ovarian cancer patients (Study SGI-110-02).

The company also announced that the ongoing clinical phase 2 expansion study (Part B of Study SGI-110-01) in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) has been expanded to approximately 200 patients by including an additional cohort of relapsed/refractory MDS patients to the ongoing three other cohorts (front-line MDS; front-line elderly AML; and relapsed/refractory AML). The phase 2 expansion trial has already enrolled more than half of the patients needed to complete the study. While data were not mature enough for presentation at the upcoming American Society of Clinical Oncology (ASCO) meeting, more mature data presentations will be submitted to other scientific conferences. The trial is still on track to submit data from the relapsed/refractory AML cohort in the phase 2 expansion study to the American Society of Hematology (ASH) meeting for presentation in December this year.

If you liked this article you might like

Trade-Ideas: Astex Pharmaceuticals (ASTX) Is Today's Pre-Market Mover With Heavy Volume Stock

Biotech Stock Mailbag: Astex Pharma, My Essential Twitter Follows

Trade-Ideas: Astex Pharmaceuticals (ASTX) Is Today's "Perilous Reversal" Stock

4 Biotech Stocks Under $10 to Trade for Breakouts

Astex Pharmaceuticals Inc Stock Downgraded (ASTX)